Capecitabina Glenmark 150 mg comprimidos recubiertos con película EFG

DRUG2 trials

Sponsors

IRCCS Istituto Nazionale Tumori Fondazione Pascale, Medica Scientia Innovation Research S.L.

Conditions

HER2 positive advanced breast cancerPatients with ras-mutated metastatIc colorectal cancer

Phase 1

PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER (The JAZMINE Study)

Not yet recruitingCTIS2025-524613-89-00

Medica Scientia Innovation Research S.L.HER2 positive advanced breast cancer

Target: 129Updated: 2026-05-05

Phase 2

REVOLUTION - Randomized phasE 2 study of Valproic acid in combination with bevacizumab and Oxaliplatin/fLUoropyrimidine regimens in patients with ras-mutated metastaTIc cOlorectal caNcer

Active, not recruitingCTIS2024-516844-25-01

IRCCS Istituto Nazionale Tumori Fondazione PascalePatients with ras-mutated metastatIc colorectal cancer

Start: 2019-01-03Target: 200Updated: 2025-07-22